CSTL

Castle Biosciences Inc

Apr 02 • 04:00PM ET

24.84

-0.21 -0.84 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: GH EXAS FLGT CDNA MYGN NTRA QDEL DGX ILMN TXG

| Held by: VTI IWM VXF IWN IBB VTWO SCHA BSVO VHT DFAT

Index	RUT	P/E	-	EPS (ttm)	-0.85	Insider Own	2.65%	Shs Outstand	29.69M	Perf Week	0.57%
Market Cap	738.52M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	-26.80%	Shs Float	28.94M	Perf Month	-11.82%
Enterprise Value	476.04M	PEG	-	EPS next Q	-0.49	Inst Own	92.13%	Short Float	4.94%	Perf Quarter	-36.14%
Income	-24.16M	P/S	2.15	EPS this Y	-41.52%	Inst Trans	-5.14%	Short Ratio	3.55	Perf Half Y	7.91%
Sales	344.23M	P/B	1.57	EPS next Y	53.67%	ROA	-4.15%	Short Interest	1.43M	Perf YTD	-36.14%
Book/sh	15.86	P/C	2.47	EPS next 5Y	66.94%	ROE	-5.21%	52W High	44.28 -43.90%	Perf Year	23.03%
Cash/sh	10.07	P/FCF	26.07	EPS past 3/5Y	31.36% -8.93%	ROIC	-4.77%	52W Low	14.59 70.25%	Perf 3Y	9.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	35.94% 40.60%	Gross Margin	68.66%	Volatility	4.26% 3.97%	Perf 5Y	-65.05%
Dividend TTM	-	EV/Sales	1.38	EPS Y/Y TTM	-229.24%	Oper. Margin	-12.44%	ATR (14)	1.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.11	Sales Y/Y TTM	3.66%	Profit Margin	-7.02%	RSI (14)	37.04	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	5.26	EPS Q/Q	-125.03%	SMA20	-2.28%	Beta	1.20	Target Price	48.50
Payout	-	Debt/Eq	0.08	Sales Q/Q	0.81%	SMA50	-18.70%	Rel Volume	0.72	Prev Close	25.05
Employees	883	LT Debt/Eq	0.07	Earnings	Feb 26 AMC	SMA200	-11.05%	Avg Volume	403.06K	Price	24.84
IPO	Jul 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	69.06% 8.91%	Trades		Volume	288,524	Change	-0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Guggenheim	Buy	$25
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$54
Jan-07-22	Initiated	Stephens	Overweight	$59
Apr-30-21	Initiated	Lake Street	Buy	$94
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$70
Dec-27-19	Reiterated	Canaccord Genuity	Buy	$34 → $35
Aug-19-19	Initiated	SVB Leerink	Outperform	$28
Aug-19-19	Initiated	Robert W. Baird	Outperform	$27
Aug-19-19	Initiated	Canaccord Genuity	Buy	$26
Aug-19-19	Initiated	BTIG Research	Buy	$25

Mar-27-26 09:05AM	Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 (PR Newswire)
Mar-13-26 11:02AM	Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB (GlobeNewswire)
Mar-09-26 07:00AM	DecisionDx-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk (GlobeNewswire)
Mar-04-26 04:30PM	Castle Biosciences to Present Data at SSO 2026 on DecisionDx-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB (GlobeNewswire)
Mar-03-26 04:30PM	Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas (GlobeNewswire)
11:43AM	Loading…
Mar-02-26 11:43AM	LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata (Zacks) -5.34%
09:10AM	REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria (Zacks)
Feb-27-26 12:46PM	RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus (Zacks) -7.25%
12:35PM	PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View (Zacks)
12:08PM	TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line (Zacks)
12:06PM	PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View (Zacks)
11:14AM	Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline (Zacks)
09:49AM	Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
09:34AM	Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway (Zacks)
08:30AM	Castle Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
12:06AM	Loading…
12:06AM	Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
Feb-26-26 06:00PM	Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
05:48PM	Castle Biosciences Q4 Earnings Call Highlights (MarketBeat)
04:05PM	Castle Biosciences Reports Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
11:44AM	Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up (Zacks)
11:40AM	Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change (Zacks)
10:54AM	ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance (Zacks)
10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks)
10:40AM	IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks (Zacks)
10:08AM	Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:52AM	ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
09:21AM	Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss (Zacks)
09:02AM	UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance (Zacks)
Feb-25-26 11:03AM	BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
10:56AM	Loading…
10:56AM	JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations (Zacks)
10:21AM	RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up (Zacks)
09:12AM	Corcept's Q4 Earnings and Revenues Fall Short of Estimates (Zacks)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
08:55AM	Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y (Zacks)
Feb-24-26 12:08PM	AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
Feb-23-26 11:12AM	Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks)
10:47AM	FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug (Zacks)
09:06AM	Viatris Stock to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-20-26 10:20AM	Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View (Zacks) -6.80%
09:59AM	Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down (Zacks)
Feb-19-26 05:46PM	Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire) -6.92%
11:59AM	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth (Zacks)
10:00AM	Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
09:53AM	Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? (Zacks)
09:45AM	Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:41AM	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients (Zacks)
Feb-17-26 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
09:15AM	Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Feb-13-26 12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
Feb-12-26 10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
Feb-11-26 10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
Feb-10-26 10:45AM	Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks)
10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
10:22AM	Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
09:35AM	Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
07:51AM	Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-06-26 11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks) -7.32%
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
08:31AM	AstraZeneca to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
07:00AM	Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 (GlobeNewswire)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks) -10.22%
Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool)
11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
08:30AM	CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
Jan-30-26 08:47AM	Viking Therapeutics to Report Q4 Earnings: Here's What to Know (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks) -7.77%
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
Jan-23-26 12:00PM	Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice (Zacks)
Jan-11-26 04:00PM	Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
Jan-02-26 10:54AM	AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation (Zacks)
08:15AM	INSM Stock Up 78% in 6 Months: Here's What You Need to Know (Zacks)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
Dec-30-25 11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-29-25 10:17AM	Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus (Zacks)
09:53AM	Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? (Zacks)
09:50AM	MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? (Zacks)
Dec-24-25 11:22AM	FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug (Zacks)
11:05AM	AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label (Zacks)
09:59AM	Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise (Zacks)
08:55AM	What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' (Zacks)
Dec-23-25 10:45AM	GILD Exercises Option to License Assembly Bio's Herpes Programs (Zacks)
10:35AM	CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies (Zacks)
10:21AM	JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis (Zacks)
03:13AM	AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised) (Zacks)
Dec-22-25 10:25AM	AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use (Zacks)

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett's esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '26	Option Exercise	2.39	550	1,314	22,029	Mar 30 06:29 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '26	Sale	25.55	3,622	92,546	3,058	Mar 30 06:29 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '26	Sale	25.55	550	14,053	21,479	Mar 30 06:29 PM
Derek Maetzold	Officer	Mar 26 '26	Proposed Sale	24.70	18,180	449,046		Mar 26 05:36 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 17 '26	Sale	25.93	18,650	483,594	22,129	Mar 19 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 18 '26	Sale	25.39	650	16,504	21,479	Mar 19 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 16 '26	Sale	25.97	17,575	456,408	40,779	Mar 17 04:36 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 13 '26	Sale	25.45	13,204	336,002	58,354	Mar 17 04:36 PM
Juvenal Tobin W	Chief Commercial Officer	Mar 12 '26	Sale	25.24	20,863	526,582	86,825	Mar 16 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 11 '26	Option Exercise	2.39	6,226	14,880	112,047	Mar 13 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 12 '26	Sale	25.28	23,179	585,942	71,558	Mar 13 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 11 '26	Sale	26.11	17,310	451,947	94,737	Mar 13 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 11 '26	Sale	26.11	3,636	94,932	3,336	Mar 13 04:10 PM
Tobin Juvenal	Chief Commercial Officer	Mar 12 '26	Proposed Sale	25.32	20,863	528,251		Mar 12 04:38 PM
Derek Maetzold	Officer	Mar 11 '26	Proposed Sale	26.13	94,204	2,461,551		Mar 11 04:52 PM
Stokes Frank	Chief Financial Officer	Mar 05 '26	Sale	27.98	6,001	167,908	60,085	Mar 09 04:13 PM
Cole G Bradley	Director	Mar 05 '26	Option Exercise	3.38	4,748	16,048	26,712	Mar 09 04:12 PM
Cole G Bradley	Director	Mar 05 '26	Sale	28.47	7,403	210,727	19,309	Mar 09 04:12 PM
Stokes Frank	Chief Financial Officer	Mar 04 '26	Option Exercise	3.38	3,800	12,844	66,086	Mar 05 05:08 PM
Stokes Frank	Chief Financial Officer	Mar 03 '26	Sale	27.44	7,000	192,073	52,483	Mar 05 05:08 PM
FRANKLIN STOKES	Officer	Mar 05 '26	Proposed Sale	28.17	6,001	169,048		Mar 05 04:28 PM
GORDON B. COLE	Director	Mar 05 '26	Proposed Sale	28.47	7,403	210,743		Mar 05 04:04 PM
FRANKLIN STOKES	Officer	Mar 03 '26	Proposed Sale	27.99	7,000	195,930		Mar 03 04:33 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Feb 03 '26	Sale	39.91	3,200	127,722	84,515	Feb 05 04:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Feb 04 '26	Sale	37.99	817	31,035	83,698	Feb 05 04:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 20 '26	Sale	40.01	4,017	160,732	87,715	Jan 22 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 05 '26	Sale	38.09	2,678	102,005	30,852	Jan 07 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 06 '26	Sale	40.10	1,339	53,689	29,513	Jan 07 04:06 PM
Derek Maetzold	Officer	Jan 05 '26	Proposed Sale	39.00	12,051	469,989		Jan 05 05:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 22 '25	Sale	40.35	830	33,490	33,530	Dec 29 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 17 '25	Sale	40.04	509	20,380	34,360	Dec 19 04:06 PM
Oelschlager Kristen M	Chief Operating Officer	Dec 17 '25	Sale	39.31	14,888	585,292	12,323	Dec 19 04:06 PM
Kristen M. Oelschlager	Officer	Dec 17 '25	Proposed Sale	39.05	14,888	581,376		Dec 17 04:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 15 '25	Sale	38.78	19,525	757,099	47,690	Dec 17 04:20 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 16 '25	Sale	38.55	12,821	494,301	34,869	Dec 17 04:20 PM
Derek Maetzold	Officer	Dec 15 '25	Proposed Sale	38.88	33,685	1,309,673		Dec 15 06:21 PM
Juvenal Tobin W	Chief Commercial Officer	Dec 11 '25	Sale	37.48	13,200	494,736	86,825	Dec 15 04:09 PM
Stokes Frank	Chief Financial Officer	Dec 11 '25	Sale	37.45	4,496	168,375	50,326	Dec 15 04:08 PM
TOBIN JUVENAL	Officer	Dec 11 '25	Proposed Sale	37.48	13,200	494,675		Dec 11 04:30 PM
FRANKLIN M. STOKES	Officer	Dec 11 '25	Proposed Sale	37.45	4,496	168,375		Dec 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 04 '25	Sale	40.03	1,339	53,600	37,547	Dec 08 04:28 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 02 '25	Sale	39.23	2,678	105,058	38,886	Dec 04 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 26 '25	Sale	40.09	4,258	170,703	41,564	Dec 01 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 25 '25	Sale	40.05	5,115	204,851	45,822	Nov 26 02:58 PM
Derek Maetzold	Officer	Nov 25 '25	Proposed Sale	39.93	10,712	427,730		Nov 25 05:11 PM
TOBIN JUVENAL	Officer	Nov 24 '25	Proposed Sale	37.88	1,301	49,282		Nov 24 04:28 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 20 '25	Option Exercise	3.38	4,693	15,862	89,288	Nov 24 04:24 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 20 '25	Sale	35.58	4,693	166,977	84,595	Nov 24 04:24 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 18 '25	Sale	34.02	2,678	91,106	50,937	Nov 20 04:07 PM
Stokes Frank	Chief Financial Officer	Nov 11 '25	Sale	35.08	5,388	189,011	43,328	Nov 13 04:08 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 11 '25	Sale	35.39	500	17,695	84,027	Nov 13 04:08 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 12 '25	Sale	35.40	200	7,080	83,827	Nov 13 04:08 PM
Oelschlager Kristen M	Chief Operating Officer	Nov 11 '25	Sale	35.10	18,932	664,513	12,323	Nov 13 04:07 PM
Kristen M. Oelschlager	Officer	Nov 11 '25	Proposed Sale	34.74	18,932	657,698		Nov 12 09:32 AM
TOBIN JUVENAL	Officer	Nov 11 '25	Proposed Sale	34.74	5,393	187,353		Nov 12 07:03 AM
FRANKLIN STOKES	Officer	Nov 11 '25	Proposed Sale	34.74	5,388	187,179		Nov 12 06:58 AM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 04 '25	Sale	30.44	6,695	203,782	56,293	Nov 06 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 05 '25	Sale	31.85	2,678	85,297	53,615	Nov 06 04:08 PM
Oelschlager Kristen M	Chief Operating Officer	Oct 31 '25	Sale	25.04	12,678	317,457	27,569	Nov 04 08:56 PM
Derek Maetzold	Officer	Nov 04 '25	Proposed Sale	31.63	13,390	423,526		Nov 04 04:53 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 20 '25	Sale	22.44	1,339	30,047	62,988	Oct 23 09:30 AM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 02 '25	Sale	22.58	1,339	30,235	64,327	Oct 06 04:11 PM
Derek Maetzold	Officer	Oct 02 '25	Proposed Sale	22.23	4,017	89,298		Oct 02 05:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 17 '25	Sale	21.97	1,339	29,419	65,666	Sep 19 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 02 '25	Sale	23.93	1,339	32,042	67,005	Sep 04 04:04 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 27 '25	Sale	22.02	12,677	279,135	141,116	Aug 29 04:04 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 27 '25	Sale	21.69	18,007	390,572	153,793	Aug 29 04:04 PM
Kristen M. Oelschlager	Officer	Aug 27 '25	Proposed Sale	21.35	18,007	384,449		Aug 27 06:15 PM
Kristen M. Oelschlager	Officer	Aug 27 '25	Proposed Sale	21.35	25,355	541,329		Aug 27 04:56 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 15 '25	Sale	20.04	1,339	26,834	68,344	Aug 19 04:04 PM
Derek Maetzold	Officer	Aug 15 '25	Proposed Sale	20.09	4,017	80,702		Aug 15 05:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 13 '25	Sale	19.50	43,019	839,043	69,683	Aug 15 04:14 PM
Derek Maetzold	Officer	Aug 13 '25	Proposed Sale	19.41	43,019	834,999		Aug 13 05:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 08 '25	Option Exercise	0.00	66,991	0	136,674	Aug 12 04:32 PM
Stokes Frank	Chief Financial Officer	Aug 08 '25	Option Exercise	0.00	9,744	0	53,072	Aug 12 04:31 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 08 '25	Option Exercise	0.00	10,640	0	174,604	Aug 12 04:31 PM
Juvenal Tobin W	Chief Commercial Officer	Aug 08 '25	Option Exercise	0.00	10,640	0	88,821	Aug 12 04:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 27 '25	Sale	20.30	17,632	357,930	3,615	Jul 01 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 27 '25	Sale	20.30	4,944	100,363	69,683	Jul 01 04:05 PM
Derek Maetzold	Officer	Jun 27 '25	Proposed Sale	20.35	16,932	344,566		Jun 27 06:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '25	Sale	21.52	4,408	94,851	4,275	Apr 23 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '25	Sale	21.52	1,236	26,596	74,627	Apr 23 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 09 '25	Sale	20.22	3,647	73,739	4,440	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 09 '25	Sale	20.22	1,023	20,684	75,863	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 08 '25	Sale	20.03	761	15,243	4,577	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 08 '25	Sale	20.03	213	4,266	76,886	Apr 10 04:07 PM
Derek Maetzold	Officer	Apr 08 '25	Proposed Sale	18.60	16,932	314,935		Apr 08 04:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CSTL

Castle Biosciences Inc

Upgrade your Finviz experience